ING Group’s Achillion Pharmaceuticals ACHN Stock Holding History

ING Group’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-15,300	Closed	-$57K	–	879
2018 Q1	$57K	Hold	15,300	–	–	﹤0.01%	709
2017 Q4	$44K	Hold	15,300	–	–	﹤0.01%	740
2017 Q3	$69K	Buy	+15,300	New	+$67.9K	﹤0.01%	809
2015 Q2	–	Sell	-80,000	Closed	-$789K	–	768
2015 Q1	$789K	Buy	+80,000	New	+$999K	﹤0.01%	630

Other funds holding ACHN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

ING Group's ACHN Position: Q2 2018 in Review

ING Group sold out of Achillion Pharmaceuticals (ACHN) in Q2 2018, closing a stake of 15,300 shares — an estimated $57K sold.

ING Group first reported a position in ACHN in Q1 2015 and held it in 4 quarters. The position peaked at $789K in Q1 2015. 124 funds tracked by Wall St. Rank hold ACHN as of Q2 2018.

ING Group reported no remaining Achillion Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
ING Group sold 15,300 Achillion Pharmaceuticals shares in Q2 2018, an estimated $57K.
ING Group first reported a position in Achillion Pharmaceuticals in Q1 2015 and held it in 4 quarters.
ING Group's Achillion Pharmaceuticals position peaked at $789K in Q1 2015.
124 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q2 2018.

Based on ING Group's 13F filing for Q2 2018, filed 10 Aug 2018.